Shanghai Yingli Pharmaceutical Co.
Latest round
- Series A
Last raised
- Feb 2021
Total raised
- $30M
Investors
- 3
About Shanghai Yingli Pharmaceutical Co.
, Ltd. is a medical company that engages in the research and development of small molecule drugs for the treatment of cancer, autoimmune diseases and metabolic disorders. The company also received new drug marketing approval from the National Drug Administration (NMPA) in November 2022 for its self-developed Linperlisib tablets, under the trade name Intarex®. The company is dedicated to the research and development of clinically unmet needs and focuses on the development of innovative chemical small molecule drugs with proprietary intellectual property rights for the treatment of cancer, autoimmune diseases and metabolic diseases, with its main products being the three types of inhibitors, namely YY-20394, YL-90148, and YL-13027.
Who invested in Shanghai Yingli Pharmaceutical Co.
3 investors across 1 round
See all investors in Shanghai Yingli Pharmaceutical Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 2, 2021
Amount
$30M
Investors
Questions about Shanghai Yingli Pharmaceutical Co.
Who invested in Shanghai Yingli Pharmaceutical Co.?
Shanghai Yingli Pharmaceutical Co. has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Shanghai Yingli Pharmaceutical Co. raised?
Shanghai Yingli Pharmaceutical Co. has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Shanghai Yingli Pharmaceutical Co. last raise money?
Shanghai Yingli Pharmaceutical Co.'s most recent round on record is a Series A, in Feb 2021.
What does Shanghai Yingli Pharmaceutical Co. do?
Shanghai Yingli Pharmaceutical Co. is a pharmaceuticals company.
Where is Shanghai Yingli Pharmaceutical Co. headquartered?
Shanghai Yingli Pharmaceutical Co. is headquartered in Shanghai, China.
Which VCs invest in companies like Shanghai Yingli Pharmaceutical Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Shanghai Yingli Pharmaceutical Co.'s stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Shanghai Yingli Pharmaceutical Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.